Working… Menu

The Effects of Dupilumab on Allergic Contact Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03935971
Recruitment Status : Not yet recruiting
First Posted : May 2, 2019
Last Update Posted : July 12, 2019
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Ari M. Goldminz, Brigham and Women's Hospital

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : September 2021